Effector Therapeutics Inc Strategic Asset Allocation Index
Effector Therapeutics Inc strategic asset allocation index. Effector Therapeutics Inc (EFTR) has a Strategic Asset Allocation Index of 11.6% as of June 2023. Strategic assets (PP&E of $299.00K plus long-term investments of $-) total $299.00K, measured against net assets of $2.58 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Effector Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Effector Therapeutics Inc (2021–2022)
Strategic asset allocation index of Effector Therapeutics Inc from 2021 to 2022. This chart shows how Effector Therapeutics Inc's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 11.6%, representing strategic assets of $299.00K against net assets of $2.58 Million USD. Check Effector Therapeutics Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Effector Therapeutics Inc Strategic Asset Allocation Index by Year (2021–2022)
Effector Therapeutics Inc strategic asset allocation index by year from 2021 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Effector Therapeutics Inc from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see EFTR market cap.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 9.0% | $352.00K | $352.00K | $- | $3.90 Million | ▲ +8.5 pp |
| 2021 | 0.5% | $91.00K | $91.00K | $- | $17.28 Million | — |